Search results for "HEP"

showing 10 items of 12243 documents

Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort

2016

Background: Natural history of primary biliary cirrhosis (PBC) is partially characterized in patients from the Mediterranean area whose genetic background differs from that of Northern Europeans. Objectives: We aimed to describe genetic susceptibility and clinical course of PBC in patients from Southern Italy. Methods: Socio-demographic, clinical, biochemical and histological data at diagnosis as well as disease progression of 81 PBC consecutive patients were collected. All subjects were treated with Ursodeoxycholic acid at a dose of 15 mg/kg. HLA class II DRB1 alleles were compared with those of 237 healthy control subjects. IL28B genotyping for IL28B rs12979860 C/T and rs80899917 G/T was …

0301 basic medicinemedicine.medical_specialtyPrimary biliary cirrhosimedicine.medical_treatmentLiver transplantationGastroenterology03 medical and health sciences0302 clinical medicinePrimary biliary cirrhosisGeneticInternal medicineGenotypemedicineGenetic predispositionProspective cohort studySettore MED/04 - Patologia GeneraleAutoimmune diseaseSettore MED/12 - GastroenterologiaPrimary Biliary CirrhosisHepatologybusiness.industrymedicine.diseaseKowsarTransplantation030104 developmental biologyInfectious DiseasesGenetic; Natural history; Primary biliary cirrhosis; Hepatology; Infectious Diseases030211 gastroenterology & hepatologybusinessResearch ArticleNatural HistoryHepatitis Monthly
researchProduct

Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis

2016

BACKGROUND Fibrosis as a common problem in patients with Crohn's disease is a result of an imbalance toward excessive tissue repair. At present, there is no specific treatment option. Pirfenidone is approved for the treatment of idiopathic pulmonary fibrosis with both antifibrotic and anti-inflammatory effects. We subsequently investigated the impact of pirfenidone treatment on development of fibrosis in a new mouse model of intestinal fibrosis. METHODS Small bowel resections from donor mice were transplanted subcutaneously into the neck of recipients. Animals received either pirfenidone (100 mg/kg, three times daily, orally) or vehicle. RESULTS After administration of pirfenidone, a signif…

0301 basic medicinemedicine.medical_specialtyPyridonesBlotting Western610 Medicine & healthGastroenterologyImmunoenzyme TechniquesMice03 medical and health sciencesIdiopathic pulmonary fibrosis0302 clinical medicineTransforming Growth Factor betaFibrosis10049 Institute of Pathology and Molecular PathologyInternal medicinemedicineAnimalsImmunology and Allergy2715 GastroenterologyCell ProliferationMice Inbred BALB CbiologyCell growthbusiness.industryAnti-Inflammatory Agents Non-SteroidalGastroenterologyPirfenidoneTransforming growth factor betamedicine.diseaseFibrosisMice Inbred C57BLTransplantationBlotDisease Models AnimalIntestinal Diseases10219 Clinic for Gastroenterology and Hepatology030104 developmental biology2723 Immunology and Allergybiology.proteinFemale030211 gastroenterology & hepatologyCollagen10069 Clinic of Cranio-Maxillofacial SurgerybusinessAfter treatmentmedicine.drugInflammatory Bowel Diseases
researchProduct

Hypoxie et régénération cardiaque : une nouvelle approche paradoxale de la cardioprotection

2017

IF 2.331; International audience

0301 basic medicinemedicine.medical_specialtyReactive oxygen species metabolismTranscription GeneticCardiac pathologyEnergy metabolismCardiac metabolismCardioprotectionHypoxie03 medical and health sciencesInternal medicinemedicineRégénérationAnimalsHumansRegenerationMyocytes CardiacTissue survivalHypoxiaCoeurCell ProliferationCardioprotectionHeart FailureTissue Survivalbusiness.industryOxygen metabolismHeartGeneral MedicineRecovery of FunctionHypoxia (medical)[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemCell HypoxiaOxygenOxidative Stress030104 developmental biologyGene Expression RegulationAnesthesiaCardiologymedicine.symptomCardiology and Cardiovascular MedicinebusinessEnergy MetabolismReactive Oxygen SpeciesSignal TransductionArchives of cardiovascular diseases
researchProduct

Minimal hepatic encephalopathy is associated with expansion and activation of CD4+CD28−, Th22 and Tfh and B lymphocytes

2017

AbstractPeripheral inflammation acts synergistically with hyperammonemia in inducing neurological alterations in cirrhotic patients with minimal hepatic encephalopathy (MHE). We hypothesized that appearance of MHE would be associated to some specific qualitative change in peripheral inflammation. The aim of this work was to characterize the changes in peripheral inflammation associated to appearance of MHE. We analyzed it by immunophenotyping and cytokine profile analysis, in cirrhotic patients without or with MHE and controls. The main alterations associated specifically with MHE are: 1) increased activation of all subtypes of CD4+ T-lymphocytes, with the increased expression of CD69; 2) i…

0301 basic medicinemedicine.medical_specialtyScienceInflammationArticleMonocytesImmunophenotyping03 medical and health sciencesImmune systemImmunophenotypingCD28 AntigensInternal medicinemedicineHumansCX3CL1Hepatic encephalopathyB-LymphocytesMultidisciplinarybusiness.industryCD69QRCD28HyperammonemiaT-Lymphocytes Helper-Inducermedicine.disease030104 developmental biologyEndocrinologyHepatic EncephalopathyImmunoglobulin GCD4 AntigensImmunologyMedicineCytokinesmedicine.symptombusinesshuman activitiesScientific Reports
researchProduct

The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update

2017

Gluten-related disorders have recently been reclassified with an emerging scientific literature supporting the concept of non-celiac gluten sensitivity (NCGS). New research has specifically addressed prevalence, immune mechanisms, the recognition of non-immunoglobulin E (non-IgE) wheat allergy and overlap of NCGS with irritable bowel syndrome (IBS)-type symptoms. This review article will provide clinicians with an update that directly impacts on the management of a subgroup of their IBS patients whose symptoms are triggered by wheat ingestion.

0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaGlutensamylase-trypsin inhibitors (ATIs)Gluten sensitivitylcsh:TX341-641Non-Celiac Gluten SensitivityReviewWheat HypersensitivityGastroenterologyIrritable Bowel Syndrome03 medical and health sciencesDiet Gluten-Free0302 clinical medicineMalabsorption Syndromesgluten-free dietMedizinische FakultätInternal medicineMedicineHumansddc:610Irritable bowel syndromeImmune mechanismsRandomized Controlled Trials as Topicgluten-related disorder030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industrygluten sensitivitynutritional and metabolic diseasesGluten-related disordersWheat-Sensitive Irritable Bowel Syndromemedicine.diseaseMalabsorption Syndromedigestive system diseasesNon-Celiac Gluten Sensitivity; Wheat-Sensitive Irritable Bowel SyndromeReview articlewheat allergy030211 gastroenterology & hepatologybusinessNon-celiac gluten sensitivitygluten-related disorderslcsh:Nutrition. Foods and food supplyWheat allergyGlutenceliac diseaseFood ScienceHuman
researchProduct

NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response

2021

AbstractBackground and AimsNon-alcoholic fatty liver disease and related hepatic syndromes affect up to one third of the adult population. The molecular mechanisms underlying NAFL etiology remain elusive. Nuclear Protein 1 (NUPR1) expression increases upon cell injury in all organs and recently we report its active participation in the activation of the Unfolded Protein Response (UPR). The UPR typically maintains protein homeostasis, but downstream mediators of the pathway regulate metabolic functions, including lipid metabolism. NUPR1 and UPR increase have been reported in obesity and liver pathologies and the goal of this study was to investigate the roles of NUPR1 in this context.Methods…

0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaPPAR-a signalling UPRPeroxisome proliferator-activated receptorContext (language use)UPRDiet High-FatBiochemistry03 medical and health sciencesLiver diseaseMice0302 clinical medicineInternal medicineCell Line TumorGeneticsmedicineBasic Helix-Loop-Helix Transcription FactorsAnimalsHomeostasisHumansMolecular Biologychemistry.chemical_classificationbusiness.industryEndoplasmic reticulumFatty liverNASHLipid metabolismlipotoxicitymedicine.diseaseEndoplasmic Reticulum StressLipid MetabolismNeoplasm Proteins030104 developmental biologyEndocrinologychemistryLipotoxicityLiverNAFLKnockout mouseUnfolded protein responseUnfolded Protein ResponsePPAR-a signallingSteatosisSteatohepatitisbusiness030217 neurology & neurosurgeryNUPR1Biotechnology
researchProduct

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nona…

2018

Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver damage and has a strong genetic component. The rs4841132 G>A variant, modulating the expression of protein phosphatase 1 regulatory subunit 3B (PPP1R3B), which is involved in glycogen synthesis, has been reported to reduce the risk of NAFLD but at the same time may favor liver disease by facilitating glycogen accumulation. The aim of this study was to assess the impact of rs4841132 on development of histologic steatosis and fibrosis in 1,388 European individuals in a liver biopsy cohort, on NAFLD hepatocellular carcinoma in a cross-sectional Italian cohort (n = 132 cases), and on liver disease at the population level in the …

0301 basic medicinemedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAPopulation03 medical and health sciencesLiver disease0302 clinical medicineLipid oxidationFibrosisInternal medicineNonalcoholic fatty liver diseasemedicineeducationNASH NAFLDeducation.field_of_studyHepatologymedicine.diagnostic_testbusiness.industryOriginal ArticlesHepatologymedicine.diseasen/a030104 developmental biologyEndocrinologyLiver biopsy030211 gastroenterology & hepatologyOriginal ArticleSteatosisbusiness
researchProduct

Staphylococcus aureus bloodstream infection in patients with prosthetic joint included in the prospective VIRSTA cohort study: frequency and time of …

2019

International audience; Among 143 patients of the VIRSTA cohort study with Staphylococcus aureus bacteremia and an arthroplasty implanted for more than a year, S. aureus periprosthetic joint infection was observed in 19%. Signs of infection (pain and swelling) were always present, in median 1 day (range, 0-21 days) after onset of bacteremia. Staphylococcus aureus has both a high potential for metastatic infection and a high affinity for foreign material. Possible prosthesis infection is of clinical concern in all patients with preexisting prosthetic materials experiencing S. aureus bloodstream infection (SAB). Prosthetic joints are especially prone to infection during the course of bacterem…

0301 basic medicinemedicine.medical_specialtyStaphylococcus aureusmedicine.medical_treatment030106 microbiologyPeriprostheticbloodstream infectionmedicine.disease_causeProsthesis03 medical and health sciences0302 clinical medicineInternal medicinemedicine030212 general & internal medicineprosthetic joint infectionProspective cohort studybusiness.industryBrief Reportmedicine.diseaseArthroplasty3. Good healthInfectious DiseasesOncologyStaphylococcus aureusBacteremiaImplantbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyCohort study
researchProduct

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society …

2021

International audience; Background and aimsThis European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.MethodsEvidence-based review.ResultsStatin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-h…

0301 basic medicinemedicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classHigh-risk2019 ESC/EAS Dyslipidaemia GuidelineLipid goal030204 cardiovascular system & hematologyTriglyceride03 medical and health sciences0302 clinical medicineCombined treatmentcardiovascular diseaseInternal medicinemedicineHumanstriglycerides2019 ESC/EAS Dyslipidaemia Guidelines; combination treatment; LDL cholesterol; triglycerides; lipid goals; high-risk; cardiovascular diseaselipid goalsbusiness.industryTask forceAnticholesteremic AgentsPCSK9Cholesterol LDL[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismAtherosclerosis2019 ESC/EAS Dyslipidaemia Guidelines3. Good health030104 developmental biologyDiabetes Mellitus Type 2Combination treatmentAtherosclerosiLDL cholesterolEuropean atherosclerosis societyKexinlipids (amino acids peptides and proteins)Proprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessVery high risk
researchProduct

Reducing Peripheral Inflammation with Infliximab Reduces Neuroinflammation and Improves Cognition in Rats with Hepatic Encephalopathy

2016

Inflammation contributes to cognitive impairment in patients with hepatic encephalopathy (HE). However, the process by which peripheral inflammation results in cognitive impairment remains unclear. In animal models, neuroinflammation and altered neurotransmission mediate cognitive impairment. Taking into account these data, we hypothesized that in rats with HE: (1) peripheral inflammation is a main contributor to neuroinflammation; (2) neuroinflammation in hippocampus impairs spatial learning by altering AMPA and/or NMDA receptors membrane expression; (3) reducing peripheral inflammation with infliximab (anti-TNF-a) would improve spatial learning; (4) this would be associated with reduced n…

0301 basic medicinemedicine.medical_specialtyTNF-ahepatic encephalopathyHippocampusMorris water navigation taskInflammationAMPA receptorNeurotransmissionlcsh:RC321-571neuroinflammation03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineInternal medicinemedicineneurotransmissionlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryMolecular BiologyNeuroinflammationOriginal Researchcognitive impairmentbusiness.industryGlutamate receptor030104 developmental biologyEndocrinologynervous systemNMDA receptormedicine.symptombusinessNeuroscience030217 neurology & neurosurgeryNeuroscience
researchProduct